Abstract

Doc number: 552

Abstract

Background: Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied.

Methods: To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR.

Results: No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer patients.

Conclusions: The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.

Details

Title
Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients
Author
Pelttari, Liisa M; Nurminen, Riikka; Gylfe, Alexandra; Aaltonen, Lauri A; Schleutker, Johanna; Nevanlinna, Heli
Pages
552
Publication year
2012
Publication date
2012
Publisher
BioMed Central
e-ISSN
14712407
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/1471-2407-12-552
ProQuest document ID
1237806840
Copyright
© 2012 Pelttari et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.